Trial Profile
A Phase 1/2 Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Mar 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Ulocuplumab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 12 Jul 2021 Results published in the Blood
- 26 May 2021 Planned primary completion date changed from 31 Jan 2021 to 31 Jan 2023.
- 03 Feb 2020 Status changed from recruiting to active, no longer recruiting.